- Conditions
- Chronic Allergic Rhinitis, Nonallergic Rhinitis
- Interventions
- Astepro Nasal Spray (0.1% azelastine hydrochloride), Astelin Nasal Spray (0.1% azelastine hydrochloride)
- Drug
- Lead sponsor
- Meda Pharmaceuticals
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 862 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- Somerset, New Jersey
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–7
of 7
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Allergic Rhinitis
- Interventions
- 205.5 mcg of azelastine hydrochloride, 137 mcg of azelastine hydrochloride
- Drug
- Lead sponsor
- Meda Pharmaceuticals
- Industry
- Eligibility
- 6 Months to 5 Years
- Enrollment
- 191 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Little Rock, Alaska • Costa Mesa, California + 9 more
- Conditions
- Perennial Allergic Rhinitis
- Interventions
- 0.15% azelastine hydrochloride, 0.1% azelastine hydrochloride, Placebo
- Drug
- Lead sponsor
- Meda Pharmaceuticals
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 581 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 43
- States / cities
- Huntington Beach, California • Long Beach, California • Los Angeles, California + 35 more
- Conditions
- Seasonal Allergic Rhinitis
- Interventions
- 0.15% azelastine hydrochloride 1644 mcg daily, 0.1% azelastine hydrochloride 1096 mcg daily, Placebo
- Drug
- Lead sponsor
- Meda Pharmaceuticals
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 526 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007
- U.S. locations
- 29
- States / cities
- Oxford, Alabama • Encinitas, California • Los Angeles, California + 25 more
- Conditions
- Seasonal Allergic Rhinitis
- Interventions
- Olopatadine HCl Nasal Spray, 0.6%, Azelastine HCl Nasal Spray, 0.1%
- Drug
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
- Conditions
- COVID-19
- Interventions
- Experimental: Primary Cohort, Placebo Comparator: Primary Cohort - Placebo
- Drug · Other
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 280 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Seasonal Allergic Rhinitis
- Interventions
- azelastine hydrochloride 0.15% Nasal Spray, azelastine hydrochloride 0.15% and Placebo, Azelastine 0.1%, Nasal Spray
- Drug
- Lead sponsor
- Meda Pharmaceuticals
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 617 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 30
- States / cities
- Fountain Valley, California • Long Beach, California • Los Angeles, California + 26 more